by Clinical Neuropsychologist Online | Wednesday, November 4, 2026 | Dementia
Abstract INTRODUCTION Harmonized cognitive composites are widely used to study longitudinal cognitive decline. Although harmonization places scores on a common latent scale, measurement precision varies across visits, age, and diagnosis, but is typically ignored in...
by Clinical Neuropsychologist Online | Wednesday, November 4, 2026 | Dementia
Abstract INTRODUCTION TAR DNA-binding protein 43 (TDP-43) proteinopathies encompass a spectrum of conditions including frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP), limbic-predominant age-related TDP-43 encephalopathy (LATE-NC), and hippocampal...
by Clinical Neuropsychologist Online | Wednesday, November 4, 2026 | Dementia
Abstract INTRODUCTION Blood-based biomarkers, particularly phosphorylated tau 217 (p-tau217), can detect early Alzheimer’s disease (AD) neuropathological changes. Recent work has shown that p-tau217 is lower in individuals with stable cognition and higher...
by Clinical Neuropsychologist Online | Wednesday, November 4, 2026 | Dementia
Abstract INTRODUCTION Combining Alzheimer’s disease blood biomarkers may improve prediction of amyloid positivity (A+) compared with single biomarkers. METHODS Logistic regression models using plasma phosphorylated tau 217 (p-tau217), amyloid beta (Aβ) 42, and...
by Clinical Neuropsychologist Online | Wednesday, November 4, 2026 | Dementia
Alzheimer’s &Dementia, Volume 22, Issue 11, November 2026. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | November 4, 2026 Neuro-Dementia...
